Antiretroviral News and Research

RSS

Low-cost antibiotic co-trimoxazole should be given to all children with HIV in developing countries

Results of a randomised trial in this week’s issue of THE LANCET highlight how the low-cost antibiotic co-trimoxazole should be given to all children with HIV in developing countries to help reduce illness and death from opportunistic infections such as pneumonia.

18 Nov 2004

Silicone facial implants provide HAART patients with a healthier appearance

Highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS is the name given to treatment regimens recommended by leading HIV experts to aggressively suppress viral replication and progress of HIV disease. These treatment regimens have been shown to reduce the amount of virus so that it becomes undetectable in a patient's blood.

16 Nov 2004

HIV drugs known as protease inhibitors also protect against Malaria

Scientists from The Queensland Institute of Medical Research (QIMR) have found that a group of HIV drugs known as protease inhibitors may also be effective for treating or preventing malaria.

11 Nov 2004

Protease inhibitors used to treat HIV-1 infection may also be effective for treatment or prevention of malaria

The study found protease inhibitors inhibited the growth of P. falciparum, the malaria parasite that causes most disease. These findings may also expose a previously unexplored vulnerability in the parasite that could lead to a new class of anti-malarial drug.

8 Nov 2004

New molecular tool to pinpoint DNA mutations among thousands of cells

Scientists have designed a new molecular tool, dubbed "LigAmp," to pinpoint DNA mutations among thousands of cells, the equivalent of searching for a single typo in an entire library of books.

28 Oct 2004

Researchers investigate new treatment options, including ways to boost immune responses to better control HIV

Highly active antiretroviral therapy (HAART) for the treatment of individuals infected by HIV-1 is limited by high costs, drug resistance, and drug-related toxicities. This has led researchers to investigate new treatment options, including ways to boost immune responses to better control HIV.

25 Oct 2004

Boehringer Ingelheim - New Drug Application (NDA) for tipranavir

The Company is seeking accelerated approval of tipranavir and has requested a priority, six-month review of the NDA. Priority review designation is based upon whether a drug provides a significant improvement in the treatment of a serious or life-threatening disease.

25 Oct 2004

FDA grants traditional approval for Fuzeon (enfuvirtide), to treat HIV

Roche and Trimeris today announced that the U.S. Food and Drug Administration (FDA) has granted traditional approval to Fuzeon (enfuvirtide), the first and only fusion inhibitor for the treatment of HIV.

18 Oct 2004

PAHO reports on the care and treatment of people with HIV in the Americas

The Pan American Health Organization (PAHO) has issued reports on the first seven of 47 countries and territories with new and specific data on the care and treatment of people with HIV in the Americas.

13 Oct 2004

One group of drugs that is effective in fighting HIV may also be promoting the death of sensory nerves in the skin

One group of drugs that is effective in fighting HIV may, paradoxically, also be promoting the death of sensory nerves in the skin, according to a study presented October 5, 2004, at the 129th annual meeting of the American Neurological Association in Toronto.

5 Oct 2004

Antiretroviral treatment may provide protection against HIV transmission during breast-feeding

Women who take combination AIDS drugs not only have benefits for their own health but also may pass along high levels of the medication through breast-feeding, potentially protecting their infants from HIV infection

30 Sep 2004

PAHO outlines health challenges ahead

Pan American Health Organization (PAHO) Director Dr. Mirta Roses today presented a report summarizing PAHO's work over the past year in the Americas, during a special session of a meeting of the region's ministers of health taking place at PAHO headquarters this week.

28 Sep 2004

Discovery of dopamine terminal injury in brains of people with HIV dementia

Scientists at the U.S. Department of Energy’s Brookhaven National Laboratory have discovered a key mechanism in the brains of people with human immunodeficiency virus (HIV) dementia.

20 Sep 2004

WHO urges Member States to act now to avoid a major HIV/AIDS epidemic

Dr Shigeru Omi, World Health Organization Regional Director for the Western Pacific, has warned of the danger of HIV "bridging" into the general population from infected individuals with high-risk behaviour unless countries and areas in the Region act now to avoid a major HIV/AIDS epidemic.

16 Sep 2004

Early use of combination-drug treatments could improve HIV survival rates

Survival rates of HIV-positive patients could be improved if combination-drug treatment were begun earlier than current clinical guidelines now recommend, according to a new study by researchers from The New York Academy of Medicine and the Johns Hopkins University Bloomberg School of Public Health.

14 Sep 2004

Researchers uncover how HIV causes abnormalities in antibody-producing cells

HIV wreaks much of its damage by targeting the “orchestra conductor” of the immune system, a key class of T cells—CD4+ T cells—whose destructive relationship with HIV has been well-studied by AIDS researchers.

8 Sep 2004

Generic tritherapy can be used as a basic treatment for AIDS

A clinical trial, conducted in Cameroon by IRD researchers working with other organizations and supported by the ANRS, has demonstrated that one of the most common combinations currently deployed in Africa, using nevirapine, stavudine and lamivudine, satisfies these criteria.

5 Sep 2004

Highly active antiretroviral therapies for AIDS are not initiated soon enough

Highly active antiretroviral therapy (HAART) has been shown to delay progression of AIDS and reduce mortality, yet the optimal time to start it is unknown.

2 Sep 2004

FDA reinforces use of Sustiva in first-line HIV combination therapy

Bristol-Myers Squibb has announced that Sustiva® (efavirenz) has received approval from the U.S. Food and Drug Administration to include new long-term virologic and clinical data from BMS Study 006 in its prescribing information.

26 Aug 2004

Clinicians have been able to reduce mortality rates in HIV positive children from 15 to 3 percent

"This is perhaps the first time that it has been demonstrated that HIV positive children can be successfully treated with antiretroviral therapy in resource-limited settings and the outcomes are comparable to those we have seen in U.S. pediatric antiretroviral clinical trials,"

23 Aug 2004